Mörén L, et al. “Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM” BMC Cancer 18:167 (2018)

Beddowes E, et al. “Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers” J Clin Oncol 35:1758-1759 (2017)

Szlosarek PW, et al, “Arginine Deprivation with Pegylated Arginine Deiminase in Patients with ASS1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial” JAMA Oncol 3:58-66 (2017)

Kremer J, et al. “Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers” Cell Rep 18: 991–1004 (2017)

Kremer J, et al. “Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect” Mol Cell Oncol Mar 1;4(3):e1295131 (2017)

Khadeir R, et al. “Optimizing arginine deprivation for hard-to-treat cancers” Oncotarget 8(57) 96468-96469 (2017)

Brin E, et al. “Pegylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration” Oncotarget 8: 58948-58963 (2017)

Thongkum A, et al. “The combination of arginine deprivation and 5-fluorouracil improves therapeutic efficacy in argininosuccinate synthetase negative hepatocellular carcinoma” Int J Mol Sci Jun 1;18(6) (2017)

Liu Q, et al. “Reduced expression of argininosuccinate synthetase 1 has a negative impact in patients with pancreatic ductal carcinoma” PLoS One, DOI:10.1371, February 10 (2017)

Long Y, et al. “Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy” Cancer Lett 388:54-63 (2017)

Tsai HJ, “A phase II study of arginine deiminase (ADI‑PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients” Scientific Reports 7, 11253 (2017)

Li Y, et al. “Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation” Mol Oncol 11:1806-1825 (2017)

Locke M, et al. “Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase” Cell Rep 16:1604-1613 (2016)

Burrows N, et al. “Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI‑PEG20)” Sci Rep Mar 14;6:22950 (2016)

Li Y, et al. “BRAF Inhibitor resistance enhances vulnerability to arginine deprivation in melanomas” Oncotarget 7:17665-17580 (2016)

Bean GR, et al. “A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.” Cell Death Dis 7:e2406 (2016)

Long Y, et al. “Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation” Oncotarget 7:82658-82670 (2016)

Miraki-Moud F, et al. “Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo” Blood 125, 4040-4048 (2015)

Savaraj N, et al. “Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin” Oncotarget 6:6295-309 (2015)

Qiu F, et al. “Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells” Science Signaling 7 (319), ra31 (2014)

Changou CA, et al. “Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy.” Proc Natl Acad Sci USA 111:14147-14152 (2014)

Allen M, et al. “Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging” Cancer Res 74:896-907 (2014)

McAlpine JA, et al. “Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy” BMC Cancer Aug 28;14:621 (2014)

Kim RH, et al. “Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis” Cancer Res 69:700-708 (2009)

Kim RH, et al. “ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer” Autophagy 5:567-568 (2009)


Contact Us

Maximum size: 12 MB